ArticleMicroorganisms2023
The Pathogenicity of
Article in Microorganisms, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 18 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
18 citing papers in PubMed, 2 syntheses or guidelines pooled it, 21 citations in OpenAlex.
- Unravelling novel microbial players in the breast tissue of TNBC patients: a meta-analytic perspective.NPJ biofilms and microbiomes · 2025Pooled it
- Adherence to the Mediterranean diet and its protective effects against colorectal cancer: a meta-analysis of 26 studies with 2,217,404 participants.GeroScience · 2025Pooled it
- Harnessing the gut microbiome for improved immune checkpoint inhibition in colorectal cancer immunotherapy: a narrative Review.Clinical and experimental medicine · 2026Review
- The intratumoral microbiome in colorectal cancer: origins, microenvironmental interactions, and new horizons in precision medicine.Frontiers in immunology · 2026Review
- From oral dysbiosis to colorectal cancer: reframing fusobacterium nucleatum as an oxidative stress-primed oncobion.Frontiers in cellular and infection microbiology · 2026Article
- Article
- Fusobacterium nucleatum enhances oxaliplatin resistance in colon cancer by increasing PVT1 expression.Journal of translational medicine · 2025Article
- Targeting Fusobacterium nucleatum in colorectal cancer: therapeutic strategies and future directions.Infectious agents and cancer · 2025Review
- Fusobacterium Nucleatum in Colorectal Cancer: Relationship Among Immune Modulation, Potential Biomarkers and Therapeutic Implications.International journal of molecular sciences · 2025Review
- Article
- Evaluating biocide efficacy in mixed-species biofilms: insights from a dual anaerobic biofilm reactor.Npj Materials degradation · 2025Article
- Fusobacterium nucleatum Abundance is Associated with Cachexia in Colorectal Cancer Patients: The ColoCare Study.Cancer medicine · 2024Article
- Current advances in cancer energy metabolism under dietary restriction: a mini review.Medical oncology (Northwood, London, England) · 2024Review
- Review
- Promising dawn in tumor microenvironment therapy: engineering oral bacteria.International journal of oral science · 2024Review
- A Longitudinal Dynamic Change in LMR Can Be a Biomarker for Recurrence in Fusobacterium Nucleatum-Positive Colorectal Cancer Patients.Journal of inflammation research · 2024Article
- Antibiotic-induced dysbiosis in the SCIME™ recapitulates microbial community diversity and metabolites modulation ofFrontiers in microbiology · 2024Article
- Gut microbiome: decision-makers in the microenvironment of colorectal cancer.Frontiers in cellular and infection microbiology · 2023Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors at 1 institution in 1 country.
Funding
Abstract
The dietary composition has been approved to be strongly associated with the risk of colorectal cancer (CRC), one of the most serious malignancies worldwide, through regulating the gut microbiota structure, thereby influencing the homeostasis of colonic epithelial cells by producing carcinogens, i.e., ammonia or antitumor metabolites, like butyrate. Though butyrate-producing
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.